EXPERIMENTAL IMMUNOLOGY
Age-related variations in the in vitro bactericidal activity of human sera against Pseudomonas aeruginosa
 
More details
Hide details
 
Submission date: 2017-01-01
 
 
Final revision date: 2017-03-15
 
 
Acceptance date: 2017-04-18
 
 
Publication date: 2018-03-30
 
 
Cent Eur J Immunol 2018;43(1):18-25
 
KEYWORDS
ABSTRACT
The human serum is a vital component of the innate immunity of the host that acts as the first line of defence against invading pathogens. A key player in serum-mediated innate immune defence is a system of more than 35 proteins, collectively named as the complement system. After exposure of the pathogen, these proteins are activated in a cascade manner, ultimately forming a membrane attack complex (MAC) on the surface of the pathogen that directly lyses the bacterial cell. Formation of the MAC can be demonstrated in vitro by using serum bactericidal assay (SBA) that works in the absence of cellular components of blood after incubating the serum along with bacteria. Here, we describe the age-related differences in the bactericidal activity of human serum against Pseudomonas aeruginosa, an opportunistic human pathogen causing an array of hospital and community-acquired infections.
We demonstrate that adult sera were highly effective in the in vitro killing of Pseudomonas aeruginosa as compared to children and the elderly (p < 0.0001). Sera from children were seriously compromised in the killing P. aeruginosa, whereas elderly sera showed a reduced level of killing. Data revealed a positive correlation between age and serum-killing with higher coefficient of determination values of 0.34, 0.27, and 0.58 and p values of < 0.0001, < 0.001, and < 0.0001, respectively, after 60, 90, and 120 minutes of incubation. Hence, our study highlights the age-related difference in the bactericidal activity of human sera. We conclude that sera of children are totally compromised, whereas elderly sera are only partially compromised, in the killing of P. aeruginosa.
REFERENCES (57)
1.
Ryan KJ, Ray CG, Sherris JC (2004): Sherris medical microbio­logy: an introduction to infectious diseases. 4th ed. New York: McGraw-Hill.
 
2.
Diekema DJ, Pfaller MA, Jones RN, et al. (1999): Survey of bloodstream infections due to gram-negative bacilli: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, and Latin America for the SENTRY Antimicrobial Surveillance Program, 1997. Clin Infect Dis 29: 595-607.
 
3.
Garnacho-Montero J, Garcia-Garmendia JL, Barrero-Almodovar A, et al. (2003): Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis. Crit Care Med 31: 2742-2751.
 
4.
Ibrahim EH, Sherman G, Ward S, et al. (2000): The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 118: 146-155.
 
5.
Owens RC, Lautenbach E (2008): Antimicrobial resistance: problem pathogens and clinical countermeasures, New York: Informa Healthcare.
 
6.
Gellatly SL, Hancock RE (2013): Pseudomonas aeruginosa: new insights into pathogenesis and host defenses. Pathog Dis 67: 159-173.
 
7.
Chastre J (2008): Evolving problems with resistant pathogens. Clin Microbiol Infect 14 Suppl 3: 3-14.
 
8.
Lavoie EG, Wangdi T, Kazmierczak BI (2011): Innate immune responses to Pseudomonas aeruginosa infection. Microbes Infect 13: 1133-1145.
 
9.
Mishra M, Ressler A, Schlesinger LS, et al. (2015): Identification of OprF as a complement component C3 binding acceptor molecule on the surface of Pseudomonas aeruginosa. Infect Immun 83: 3006-3014.
 
10.
Zhang J, Koh J, Lu J, et al. (2009): Local inflammation induces complement crosstalk which amplifies the antimicrobial response. PLoS Pathog 5: e1000282.
 
11.
Rhein LM, Perkins M, Gerard NP, et al. (2008): FcgammaRIII is protective against Pseudomonas aeruginosa pneumonia. Am J Respir Cell Mol Biol 38: 401-406.
 
12.
Mueller-Ortiz SL, Drouin SM, Wetsel RA (2004): The alternative activation pathway and complement component C3 are critical for a protective immune response against Pseudomonas aeruginosa in a murine model of pneumonia. Infect Immun 72: 2899-2906.
 
13.
Younger JG, Shankar-Sinha S, Mickiewicz M, et al. (2003): Murine complement interactions with Pseudomonas aeruginosa and their consequences during pneumonia. Am J Respir Cell Mol Biol 29: 432-438.
 
14.
Hopken UE, Lu B, Gerard NP, et al. (1996): The C5a chemoattractant receptor mediates mucosal defence to infection. Nature 383: 86-89.
 
15.
Trouw LA, Daha MR (2011): Role of complement in innate immunity and host defense. Immunol Lett 138: 35-37.
 
16.
Desar IM, Van Deuren M, Sprong T, et al. (2009): Serum bactericidal activity against Helicobacter pylori in patients with hypogammaglobulinaemia. Clin Exp Immunol 156: 434-439.
 
17.
Kwil I, Kazmierczak D, Rozalski A (2013): Swarming growth and resistance of Proteus penneri and Proteus vulgaris strains to normal human serum. Adv Clin Exp Med 22: 165-175.
 
18.
Jang MS, Sahastrabuddhe S, Yun CH, et al. (2016): Serum bactericidal assay for the evaluation of typhoid vaccine using a semi-automated colony-counting method. Microb Pathog 97: 19-26.
 
19.
Futoma-Koloch B, Bugla-Ploskonska G (2009): The efficiency of the bactericidal action of serum raised by complement and lysozyme against bacteria which avoid the immunological response of higher organisms. Postepy Hig Med Dosw (Online) 63: 471-484.
 
20.
Goh YS, Maclennan CA (2013): Invasive African nontyphoidal Salmonella requires high levels of complement for cell-free antibody-dependent killing. J Immunol Methods 387: 121-129.
 
21.
O’shaughnessy CM, Cunningham AF, Maclennan CA (2012): The stability of complement-mediated bactericidal activity in human serum against Salmonella. PLoS One 7: e49147.
 
22.
Mcintosh ED, Broker M, Wassil J, et al. (2015): Serum bactericidal antibody assays – the role of complement in infection and immunity. Vaccine 33: 4414-4421.
 
23.
Meshulam T, Verbrugh H, Verhoef J (1982): Serum-induced lysis of Pseudomonas aeruginosa. Eur J Clin Microbiol 1: 1-6.
 
24.
Meshulam T, Verbrugh HA, Verhoef J (1982): Opsonization and phagocytosis of mucoid and non-mucoid Pseudomonas aeruginosa strains. Eur J Clin Microbiol 1: 112-117.
 
25.
Baltimore RS, Shedd DG (1983): The role of complement in the opsonization of mucoid and non-mucoid strains of Pseudomonas aeruginosa. Pediatr Res 17: 952-958.
 
26.
Nakae T, Tanaka J, Nakano A, et al. (2008): Complement-mediated bactericidal effect of antibodies in human intravenous preparation against multi-drug resistant pseudomonas aeruginosa. Jpn J Antibiot 61: 379-387.
 
27.
Jankowski S, Grzybek-Hryncewicz K, Kopec W, et al. (1988): Bactericidal activity of human sera with a physiologic or genetic defect of the complement system. Acta Microbiol Pol 37: 309-315.
 
28.
Peterson PK, Kim Y, Schmeling D, et al. (1978): Complement-mediated phagocytosis of Pseudomonas aeruginosa. J Lab Clin Med 92: 883-894.
 
29.
Offredo-Hemmer C, Berche P, Veron M (1983): A complement-sensitive mutant of Pseudomonas aeruginosa. Ann Micro­biol (Paris) 134A: 281-294.
 
30.
Hazlett LD, Masinick-Mcclellan SA, Barrett RP (1999): Complement defects in aged mice compromise phagocytosis of Pseudomonas aeruginosa. Curr Eye Res 19: 26-32.
 
31.
Mueller-Ortiz SL, Hollmann TJ, Haviland DL, et al. (2006): Ablation of the complement C3a anaphylatoxin receptor causes enhanced killing of Pseudomonas aeruginosa in a mouse model of pneumonia. Am J Physiol Lung Cell Mol Physiol 291: L157-165.
 
32.
Moller-Kristensen M, Ip WK, Shi L, et al. (2006): Deficiency of mannose-binding lectin greatly increases susceptibility to postburn infection with Pseudomonas aeruginosa. J Immunol 176: 1769-1775.
 
33.
Chalmers JD, Fleming GB, Hill AT, et al. (2011): Impact of mannose-binding lectin insufficiency on the course of cystic fibrosis: A review and meta-analysis. Glycobiology 21: 271-282.
 
34.
Taylor PW (1983): Bactericidal and bacteriolytic activity of serum against gram-negative bacteria. Microbiol Rev 47: 46-83.
 
35.
Leddy JP, Steigbigel RT (1979): Complement, serum bactericidal activity, and disseminated gram-negative infection. Ann Intern Med 90: 984-985.
 
36.
Olling S (1977): Sensitivity of gram-negative bacilli to the serum bactericidal activity: a marker of the host-parasite relationship in acute and persisting infections. Scand J Infect Dis Suppl: 1-40.
 
37.
Vitkauskiene A, Scheuss S, Sakalauskas R, et al. (2005): Pseudomonas aeruginosa strains from nosocomial pneumonia are more serum resistant than P. aeruginosa strains from noninfectious respiratory colonization processes. Infection 33: 356-361.
 
38.
Kays MB, White RL, Friedrich LV (2001): Effect of serum from different patient populations on the serum bactericidal test. J Antimicrob Chemother 48: 417-420.
 
39.
Noguchi H, Bronfenbrenner J (1911): Effects of Mechanical Agitation and of Temperature Upon Complement. J Exp Med 13: 229-233.
 
40.
Pohl AW, Rutstein DD (1944): The Deterioration of Complement Activity in Normal Human Serum. J Clin Invest 23: 177-180.
 
41.
Siggins MK, Cunningham AF, Marshall JL, et al. (2011): Absent bactericidal activity of mouse serum against invasive African nontyphoidal Salmonella results from impaired complement function but not a lack of antibody. J Immunol 186: 2365-2371.
 
42.
Jankowski S (1995): The role of complement and antibodies in the impaired bactericidal activity of neonatal sera against gram-negative bacteria. Acta Microbiol Pol 44: 5-14.
 
43.
Gondwe EN, Molyneux ME, Goodall M, et al. (2010): Importance of antibody and complement for oxidative burst and killing of invasive nontyphoidal Salmonella by blood cells in Africans. Proceedings of the National Academy of Sciences of the United States of America 107: 3070-3075.
 
44.
Mcgreal EP, Hearne K, Spiller OB (2012): Off to a slow start: under-development of the complement system in term newborns is more substantial following premature birth. Immunobiology 217: 176-186.
 
45.
Hogasen AK, Overlie I, Hansen TW, et al. (2000): The analysis of the complement activation product SC5 b-9 is applicable in neonates in spite of their profound C9 deficiency. J Perinat Med 28: 39-48.
 
46.
Lassiter HA, Watson SW, Seifring ML, et al. (1992): Complement factor 9 deficiency in serum of human neonates. J Infect Dis 166: 53-57.
 
47.
Davis CA, Vallota EH, Forristal J (1979): Serum complement levels in infancy: age related changes. Pediatr Res 13: 1043-1046.
 
48.
De Benedetti F, Auriti C, D’urbano LE, et al. (2007): Low serum levels of mannose binding lectin are a risk factor for neonatal sepsis. Pediatr Res 61: 325-328.
 
49.
Hilgendorff A, Schmidt R, Bohnert A, et al. (2005): Host defence lectins in preterm neonates. Acta Paediatr 94: 794-799.
 
50.
Sallenbach S, Thiel S, Aebi C, et al. (2011): Serum concentrations of lectin-pathway components in healthy neonates, children and adults: mannan-binding lectin (MBL), M-, L-, and H-ficolin, and MBL-associated serine protease-2 (MASP-2). Pediatr Allergy Immunol 22: 424-430.
 
51.
Swierzko AS, Atkinson AP, Cedzynski M, et al. (2009): Two factors of the lectin pathway of complement, l-ficolin and mannan-binding lectin, and their associations with prematurity, low birthweight and infections in a large cohort of Polish neonates. Mol Immunol 46: 551-558.
 
52.
Weiskopf D, Weinberger B, Grubeck-Loebenstein B (2009): The aging of the immune system. Transpl Int 22: 1041-1050.
 
53.
Simon AK, Hollander GA, Mcmichael A (2015): Evolution of the immune system in humans from infancy to old age. Proc Biol Sci 282: 20143085.
 
54.
Yoshikawa TT (2000): Epidemiology and unique aspects of aging and infectious diseases. Clin Infect Dis 30: 931-933.
 
55.
Polignano A, Tortorella C, Venezia A, et al. (1994): Age-associated changes of neutrophil responsiveness in a human healthy elderly population. Cytobios 80: 145-153.
 
56.
Hazlett LD, Rosen DD, Berk RS (1978): Age-related susceptibility to Pseudomonas aeruginosa ocular infections in mice. Infect Immun 20: 25-29.
 
57.
Berk RS, Iglewski BH, Hazlett LD (1981): Age-related susceptibility of mice to ocular challenge with Pseudomonas aeruginosa exotoxin A. Infect Immun 33: 90-94.
 
eISSN:1644-4124
ISSN:1426-3912
Journals System - logo
Scroll to top